ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 3, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 3, 2011
News
FDA Establishes Two Centers for Regulatory Science
By Erik Greb
On Oct. 26, 2011, FDA dedicated $2 million to support two regional Centers of Excellence in Regulatory Science and Innovation. The centers, which will be located at the University of Maryland and at Georgetown University, will focus on the scientific knowledge and training needed to modernize and improve the ways the agency reviews and evaluates drugs and medical devices.
President Obama Issues Executive Order to Reduce Drug Shortages
By Amy Ritter
In response to the increase in drug shortages over the past three years, President Obama issued an executive order on Oct. 31, 2011 that directs FDA to take several steps to prevent and reduce drug shortages.
MHRA Drives for Regulatory Excellence
By Rich Whitworth
The Medicines and Healthcare products Regulatory Agency (MHRA) launched a public consultation on the consolidation of United Kingdom (UK) medicines legislation on Oct. 26, 2011. Seeking to greatly simplify and elucidate the law regulating medicines in the UK, the MHRA invited interested parties to contribute to legislation development.
Week of Oct. 31, 2011: Pfizer Completes Acquisition of Icagen; 3M Drug Delivery Systems Names James Ingebrand Vice-President and General Manager; and More
Pfizer Completes Acquisition of Icagen; 3M Drug Delivery Systems Names James Ingebrand Vice-President and General Manager; and More.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here